Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.38 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.38 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | EED | O75530 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28865454 | 0.98 | MEN1 (0.37) | MEN1NPC1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL104411 | 0.71 | MEN1 (0.38) | MEN1NPC1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL6261842 | 0.71 | ADORA2A (0.42) | MEN1NPC1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL824960 | 0.71 | NPC1 (0.46) | MEN1NPC1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL276859 | 0.71 | ADORA2A (0.42) | MEN1NPC1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL3798990 | 0.71 | CYP1A2 (0.41) | MEN1NPC1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL2007380 | 0.71 | MEN1 (0.38) | MEN1NPC1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL288995 | 0.71 | MEN1 (0.38) | MEN1NPC1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL2589546 | 0.71 | MEN1 (0.38) | MEN1NPC1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL5424464 | 0.71 | MEN1 (0.38) | MEN1NPC1CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10689396-B2 | Inhibitors of Bruton's tyrosine kinase and methods of their use | JANSSEN PHARMACEUTICA NV (BE) | 2020-06-23 | — | — | US | claimed |
| EP-3386992-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE | Janssen Pharmaceutica, N.V. (BE) | 2018-10-17 | — | — | EP | claimed |
| WO-2018103058-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2018-06-14 | — | — | WO | claimed |
| US-20170283431-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHOD OF THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2017-10-05 | — | — | US | claimed |
| WO-2017100668-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2017-06-15 | — | — | WO | claimed |
| US-11884673-B2 | Modulators of ion channel receptors and uses thereof | BIONOMICS LIMITED (AU) | 2024-01-30 | — | — | US | disclosed |
| EP-3615502-B1 | THERAPEUTIC COMPOUNDS AND METHODS | UNIV TASMANIA (AU) | 2023-06-21 | — | — | EP | disclosed |
| CN-113105475-B | Inhibitors of bruton's tyrosine kinase and methods of use thereof | 詹森药业有限公司 | 2022-09-09 | — | — | CN | disclosed |
| US-11384085-B2 | Modulators of ion channel receptors and uses thereof | BIONOMICS LIMITED (AU) | 2022-07-12 | — | — | US | disclosed |
| US-20210230157-A1 | PAIN TREATING COMPOUNDS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2021-07-29 | — | — | US | disclosed |
| US-20210230165-A1 | MODULATORS OF ION CHANNEL RECEPTORS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2021-07-29 | — | — | US | disclosed |
| CN-113105475-A | Inhibitors of bruton's tyrosine kinase and methods of use thereof | 詹森药业有限公司 | 2021-07-13 | — | — | CN | disclosed |
| EP-1819692-A1 | 3-ETHYLIDENEHYDRAZINO SUBSTITUTED HETEROCYCLIC COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS | Nissan Chemical Industries, Ltd. (JP) | 2007-08-22 | — | — | EP | disclosed |
| WO-2007005450-A2 | IMPROVED PROCESS FOR PREPARING (DISUBSTITUTEDPROPENYL) PHENYLALKYL SUBSTITUTED HETEROCYCLES | BAYER CROPSCIENCE AG (DE) | 2007-01-11 | — | — | WO | disclosed |
| WO-2006096911-A1 | NOVEL POTASSIUM CHANNEL BLOCKERS AND USES THEREOF | HARVEY ANDREW J (AU) | 2006-09-21 | — | — | WO | disclosed |
| CN-1798739-A | 3-alkylidenehydrazino substituted heteroaryl compounds as thrombopoietin receptor activators | NISSAN CHEMICAL IND LTD (JP) | 2006-07-05 | — | — | CN | disclosed |
| WO-2006062240-A1 | 3-ETHYLIDENEHYDRAZINO SUBSTITUTED HETEROCYCLIC COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2006-06-15 | — | — | WO | disclosed |
| US-20060094694-A1 | Heterocyclic compounds and thrombopoietin receptor activators | NISSAN CHEMICAL INDUSTRIES LIMITED (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1636192-A1 | 3-ALKYLIDENEHYDRAZINO SUBSTITUTED HETEROARYL COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS | Nissan Chemical Industries, Ltd. (JP) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004108683-A1 | 3-ALKYLIDENEHYDRAZINO SUBSTITUTED HETEROARYL COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10689396-B2 | Inhibitors of Bruton's tyrosine kinase and methods of their use | ABL1, BTK, MYLK2 | MEN1 2461/4885NPC1 3143/4885CYP1A2 2987/4885 |
| US-20210230165-A1 | MODULATORS OF ION CHANNEL RECEPTORS AND USES THEREOF | TRPV1, TRPM8, TRPV2 | MEN1 4751/4885NPC1 1634/4885CYP1A2 4264/4885 |
| US-20060094694-A1 | Heterocyclic compounds and thrombopoietin receptor activators | NR2C2, ROR1, NR0B2 | MEN1 2504/4885NPC1 4052/4885CYP1A2 434/4885 |
| US-20210230157-A1 | PAIN TREATING COMPOUNDS AND USES THEREOF | TRPV1, TRPA1, TRPV3 | MEN1 4244/4885NPC1 1070/4885CYP1A2 2613/4885 |
| US-11384085-B2 | Modulators of ion channel receptors and uses thereof | TRPV1, TRPM8, TRPV2 | MEN1 4751/4885NPC1 1634/4885CYP1A2 4264/4885 |
| US-11884673-B2 | Modulators of ion channel receptors and uses thereof | TRPV1, TRPM8, TRPV2 | MEN1 4751/4885NPC1 1634/4885CYP1A2 4264/4885 |
| US-20170283431-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHOD OF THEIR USE | ABL1, BTK, MYLK2 | MEN1 2551/4885NPC1 3187/4885CYP1A2 2465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.